Part of grant will fund UCSF work to profile 2,000 prescription drugs against key liver and kidney transporters. Transporter assay services firm Optivia Biotechnologies won a $1.85 million Phase II ...
Optivia Biotechnology has received a $1.8 million SBIR grant to advance the understanding of central nervous system (CNS) physiology and create novel tools to help design new CNS drugs, identify new ...
Optivia Biotechnology Inc. said Tuesday it received a $1.85 million federal grant to determine precise mechanisms that underlie some drug-to-drug interactions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback